Cannabinoid receptor agonist as an alternative drug in 5-fluorouracil-resistant gastric cancer cells
| Autor: | Xiang-Shu, Xian, Hyeyeon, Park, Myung-Gyu, Choi, Jae Myung, Park |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Cannabinoid Receptor Agonists
Antimetabolites Antineoplastic Caspase 3 Cell Survival Morpholines Antineoplastic Agents Apoptosis Naphthalenes Benzoxazines Proto-Oncogene Proteins c-bcl-2 Drug Resistance Neoplasm Stomach Neoplasms Cell Line Tumor Humans Fluorouracil Poly(ADP-ribose) Polymerases Extracellular Signal-Regulated MAP Kinases Receptors Cannabinoid Proto-Oncogene Proteins c-akt Cell Proliferation bcl-2-Associated X Protein |
| Zdroj: | Anticancer research. 33(6) |
| ISSN: | 1791-7530 |
| Popis: | Fluorouracil is the main chemotherapeutic drug used for gastrointestinal cancers, which suffers the important problem of treatment resistance. There is little information whether cannabinoid agonists can be used as an alternative drug for fluorouracil-resistant gastric cancer cells. In this study, we investigated the effects of a cannabinoid agonist, WIN-55,212-2, on 5-fluorouracil (5-FU)-resistant human gastric cancer cells, to examine whether the cannabinoid agonist may be an alternative therapy. Survival of the 5-FU-resistant gastric cancer cell line, SNU-620-5FU/1000, was not significantly reduced even by a high dose of 5-FU treatment. However, WIN-55,212-2 inhibited the proliferation of SNU-620-5FU/1000 and enhanced their apoptosis, as indicated by an increase of apoptotic cell proportion, activated caspase-3 and Poly (ADP-ribose) polymerase cleavage. Furthermore, WIN-55,212-2 reduced phospho-extracellular-signal-regulated kinases (ERK) 1/2, phospho-Akt (protein kinase B), B-cell lymphoma-2 (BCL2) and BCL2-associated X (BAX) protein expression in 5-FU-resistant gastric cancer cells. These results indicate that a cannabinoid agonist may, indeed, be an alternative chemotherapeutic agent for 5-FU-resistant gastric cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|